Pembrolizumab for Early Triple-Negative Breast Cancer
2020 · New England Journal of Medicine · 2,944 citations
https://doi.org/10.1056/nejmoa1910549
J
Joyce O’Shaughnessy
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
451
Papers
25.8K
Citations
61
h-index
158
i10-index
Joyce O’Shaughnessy is an academic researcher from Baylor University. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research. The author has an h-index of 61, co-authored 384 publications.
ORCID: 0000-0002-2955-5523Papers by this author
worksRibociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2016 · New England Journal of Medicine · 1,957 citations
https://doi.org/10.1056/nejmoa1609709
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
2021 · New England Journal of Medicine · 1,447 citations
https://doi.org/10.1056/nejmoa2028485
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
2011 · Journal of Clinical Oncology · 1,054 citations
https://doi.org/10.1200/jco.2010.28.0982
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
2018 · Annals of Oncology · 839 citations
https://doi.org/10.1093/annonc/mdy155
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
2019 · New England Journal of Medicine · 815 citations
https://doi.org/10.1056/nejmoa1814213
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat